Zidesamtinib
Brand names: Jideytro · Active ingredient: Zidesamtinib
In short: JIDEYTRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor .
What is Zidesamtinib used for?
JIDEYTRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor .
Zidesamtinib dosage
Before initiating JIDEYTRO, evaluate creatine phosphokinase (CPK) level, electrocardiogram (ECG), electrolytes, lipase and amylase .
The recommended dosage of JIDEYTRO is 100 mg taken orally once daily, with or without food, until disease progression or unacceptable toxicity .
Swallow JIDEYTRO tablets whole. Do not split, chew, crush, or dissolve the tablet prior to swallowing.
Missed Dose
If a dose of JIDEYTRO is missed within 12 hours of the regularly scheduled dose, administer the missed dose as soon as possible. If a dose is missed by 12 hours or more, take the next dose at its scheduled time.
Vomiting
If vomiting occurs at any time after taking JIDEYTRO, take the next dose at its scheduled time.
The recommended dosage reductions of JIDEYTRO for the management of adverse reactions are provided in
Table 1
.
Dose Reduction | Recommended Dose and Schedule
First | 75 mg once daily
Second | 50 mg once daily
Permanently discontinue JIDEYTRO in patients unable to tolerate 50 mg once daily.After dose reduction of JIDEYTRO for adverse reactions, do not re-escalate the dose.
The recommended dosage modifications of JIDEYTRO for the management of adverse reactions are provided in Table 2.
*Graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
Adverse Reaction | Severity* | Dosage Modification
Central Nervous System Adverse Reactions
| Intolerable Grade 2 | Withhold JIDEYTRO until Grade ≤ 1 or baseline.
Resume JIDEYTRO at same or reduced dose, as clinically appropriate.
Grade 3 | Withhold JIDEYTRO until Grade ≤ 1 or baseline.
Resume JIDEYTRO at reduced dose.
Grade 4 | Permanently discontinue JIDEYTRO.
QTc Interval Prolongation | Grade 2 (QTc interval 481-500 msec) | Withhold JIDEYTRO until recovery to Grade ≤ 1 or baseline.
Correct electrolytes and/or change concomitant medications.
Resume JIDEYTRO at same dose.
Grade 3 (QTc interval≥501 msec or QTc interval increase of >60 msec from baseline) | Withhold JIDEYTRO until recovery to Grade ≤ 1 or baseline.
Correct electrolytes and/or change concomitant medications.
Resume JIDEYTRO at a reduced dose.
Grade 4 (Torsade de pointes; polymorphic ventricular tachycardia; signs/symptoms of serious arrhythmia) | Permanently discontinue JIDEYTRO.
Interstitial Lung Disease (ILD)/Pneumonitis
| Grade 1 | Withhold JIDEYTRO if ILD/pneumonitis occurs or is suspected until recovery to Grade 0.
If resolved within 6 weeks, resume JIDEYTRO at the same dose.
If unresolved after 6 weeks, permanently discontinue JIDEYTRO.
Recurrence:
Permanently discontinue JIDEYTRO.
Grade 2 | Withhold JIDEYTRO if ILD/pneumonitis occurs or is suspected until recovery to Grade 0 or baseline.
If resolved within 6 weeks, resume JIDEYTRO at a reduced dose. …
How to take Zidesamtinib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Central Nervous System Adverse Reactions
Advise patients of the risk of central nervous system (CNS) adverse reactions during treatment with JIDEYTRO and to inform their healthcare provider if they experience new or worsening CNS symptoms. Advise patients to avoid engaging in hazardous tasks that require mental alertness and motor coordination such as operating machinery or driving a motor vehicle if they are experiencing CNS reactions .
QTc Prolongation
Advise patients of the risks of QTc interval prolongation during treatment with JIDEYTRO. Advise patients to contact their healthcare provider immediately to report signs or symptoms of arrhythmias .
Interstitial Lung Disease/Pneumonitis
Advise patients of the risks of ILD/pneumonitis during treatment with JIDEYTRO. Advise patients to inform their healthcare provider if they experience new or worsening pulmonary symptoms indicative of ILD/pneumonitis .
Skeletal Fractures
Advise patients that bone fractures have occurred in patients taking JIDEYTRO and to report signs or symptoms of fracture to their healthcare provider . …
Warnings & precautions
Do not take this medicine if: None.
JIDEYTRO can cause central nervous system adverse reactions.
In the pooled safety population , a broad spectrum of central nervous system (CNS) adverse reactions, including dizziness, ataxia, cognitive and psychiatric disorders, occurred in 25% of patients who received JIDEYTRO; of these, 2.5% were Grade 3 or 4. One patient (0.2%) with brain metastases experienced a Grade 3 seizure.
Dizziness, including vertigo, presyncope and positional dizziness occurred in 12% of patients who received JIDEYTRO; of these 0.2% were Grade 3. The median time to onset of dizziness was 22 days (range: 1 day to 9 months). Dosage interruption of JIDEYTRO for dizziness was required in 0.4% of patients, and 0.7% of patients required dose reduction.
Ataxia, including gait disturbance and balance disorder, occurred in 2% of patients who received JIDEYTRO and were all Grade 1 or 2. The median time to onset of ataxia was 64 days (range: 6 days to 2.5 years).
Cognitive impairment occurred in 9% of patients who received JIDEYTRO, of these 1.6% were Grade 3 or 4. Cognitive impairment included memory impairment (3.1%), cognitive disorder (1.6%), hallucination (1.1%), delirium (1.1%), aphasia (0.9%), amnesia (0.7%), confusional state (0.7%), anterograde amnesia (0.2%), disturbance in attention (0.4%), slow speech (0.2%). The median time to onset of cognitive impairment was 43 days (range: 4 days to 1.9 years). Dose interruption of JIDEYTRO for cognitive impairment was required in 1.3% of patients.
Psychiatric disorders occurred in 6% of patients who received JIDEYTRO, of these 0.7% were Grade 3 or 4. Psychiatric disorders included anxiety (3.1%), depression (1.3%), agitation (0.7%), affect lability (0.4%), irritability (0.4%), abnormal behavior (0.2%), depressed mood (0.2%), personality change (0.2%), psychotic disorder (0.2%), and suicidal ideation (0.2%). …
Zidesamtinib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Central Nervous System Adverse Reactions
QTc Interval Prolongation
Interstitial Lung Disease/Pneumonitis
Skeletal Fractures
Myalgia with Creatine Phosphokinase Elevation
Pancreatic Toxicity
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The pooled safety population described in WARNINGS AND PRECAUTIONS reflects exposure to JIDEYTRO in 446 patients with ROS1-positive NSCLC (n=432) and other solid tumors (n=14) who received JIDEYTRO at a dose of 100 mg orally once daily until disease progression or unacceptable toxicity in ARROS-1 . Among 446 patients who received JIDEYTRO, 44% were exposed for 6 months or longer and 14% were exposed for greater than one year. In this pooled safety population, the most common (≥15%) adverse reactions included: edema (38%), peripheral neuropathy (25%), constipation (17%), fatigue (16%), dyspnea (15%). The most common Grade 3 or 4 laboratory abnormalities (≥2%), were increased lipase (8%), increased creatine phosphokinase (CPK) (4%), increased triglycerides (3.5%), decreased lymphocytes (2.7%), and decreased hemoglobin (2.3%).
Previously Treated ROS1-positive NSCLC
The safety of JIDEYTRO was evaluated in ARROS-1
. …
Drug interactions
Strong and Moderate CYP3A Inhibitors
Avoid concomitant use of JIDEYTRO with a strong or moderate CYP3A inhibitor.
Zidesamtinib is a CYP3A substrate. Concomitant use with a strong or moderate CYP3A inhibitor increases zidesamtinib exposure , which may increase the risk of JIDEYTRO adverse reactions.
Strong and Moderate CYP3A Inducers
Avoid concomitant use of JIDEYTRO with strong or moderate CYP3A inducers.
Concomitant use of JIDEYTRO with a strong or moderate CYP3A inducer may decrease zidesamtinib exposure , which may decrease the effectiveness of JIDEYTRO.
About this medicine
Zidesamtinib is a kinase inhibitor. The molecular formula for zidesamtinib is C22H22FN7O and the molecular weight is 419.46 Daltons. The chemical name is (R)-3-Ethyl-16-fluoro-10-methyl-19-methyl-20-oxa-3,4,9,10,11,23-hexaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-ylamine. The chemical structure of zidesamtinib is as follows:
Zidesamtinib is a white to tan powder with a pKa of 4.89. The aqueous solubility of zidesamtinib at 37°C is pH dependent, decreasing from 25 mg/mL at pH 2.5 to less than 0.1 mg/mL at pH 7.9. The log of the distribution coefficient (octanol/water) at pH 7.4 is 3.01.
JIDEYTRO (zidesamtinib) tablets for oral use are supplied as 25 mg and 100 mg dosage strengths. JIDEYTRO tablets, 25 mg are film-coated, oblong, pink tablets, debossed with "25" on one side and "ZDS" on the other side of the tablet. JIDEYTRO tablets, 100 mg are film-coated, oblong, yellow tablets, debossed with "100" on one side and "ZDS" on the other side of the tablet. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 3760e421-b523-4d9b-e063-6394a90ab94b. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate